Alto Neuroscience's share price surged over plans to accelerate the development of a potential depression drug, ALTO-207. The company aims to start a mid-stage trial by mid-2022 and a late-stage study by early 2027, backed by a recent FDA meeting.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing